NasdaqGS - Nasdaq Real Time Price • USD
Lexicon Pharmaceuticals, Inc. (LXRX)
At close: 4:00 PM EDT
After hours: 4:20 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.2 | -0.18 | -0.71 | -0.66 |
| Low Estimate | -0.2 | -0.21 | -0.75 | -0.69 |
| High Estimate | -0.19 | -0.15 | -0.67 | -0.62 |
| Year Ago EPS | -0.17 | -0.22 | -0.79 | -0.71 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 1.37M | 2.97M | 25.81M | 69.3M |
| Low Estimate | 1M | 1.8M | 10.8M | 40.1M |
| High Estimate | 2.1M | 4.1M | 40.13M | 103.09M |
| Year Ago Sales | 24k | -- | 1.2M | 25.81M |
| Sales Growth (year/est) | 5,608.30% | -- | 2,043.70% | 168.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.18 | -0.17 | -0.21 | -0.22 |
| EPS Actual | -0.17 | -0.22 | -0.21 | -0.2 |
| Difference | 0.01 | -0.05 | 0 | 0.02 |
| Surprise % | 5.60% | -29.40% | 0.00% | 9.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.2 | -0.18 | -0.71 | -0.66 |
| 7 Days Ago | -0.2 | -0.18 | -0.71 | -0.66 |
| 30 Days Ago | -0.2 | -0.18 | -0.71 | -0.66 |
| 60 Days Ago | -0.23 | -0.21 | -0.78 | -0.64 |
| 90 Days Ago | -0.22 | -0.2 | -0.73 | -0.55 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | LXRX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -17.60% | -- | -- | 6.50% |
| Next Qtr. | 18.20% | -- | -- | 12.00% |
| Current Year | 10.10% | -- | -- | 5.30% |
| Next Year | 7.00% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 54.70% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Hold | 4/23/2024 |
| Reiterates | Needham: Hold | 4/11/2024 |
| Maintains | Citigroup: Buy to Buy | 5/31/2023 |
| Maintains | Needham: Hold | 5/30/2023 |
| Initiated | Jefferies: Hold | 3/7/2023 |
| Maintains | Citigroup: Buy to Buy | 11/22/2022 |
Related Tickers
AXSM Axsome Therapeutics, Inc.
71.71
+0.27%
MCRB Seres Therapeutics, Inc.
0.8250
+11.08%
EYEN Eyenovia, Inc.
0.6282
-11.68%
RIGL Rigel Pharmaceuticals, Inc.
1.1000
0.00%
ANVS Annovis Bio, Inc.
18.01
+32.43%
IOVA Iovance Biotherapeutics, Inc.
11.64
+0.87%
ADAP Adaptimmune Therapeutics plc
1.0750
+1.42%
AKBA Akebia Therapeutics, Inc.
1.3400
+0.75%
CDTX Cidara Therapeutics, Inc.
12.63
-2.85%
SAVAW Cassava Sciences, Inc.
0.4200
+35.48%